Given the fact that SF3B1 and CHEK2 inhibition and their combination present with very low toxicity against hematopoietic progenitor cells and in preclinical models [our current study and (26)], splicing-based drug combinations comprise a potential strategy for improving the efficacy of treatment and overcoming resistance in T-ALL with no significant associated toxicity. This evidence concerns the gene SF3B1 and acute lymphoblastic leukemia.